Roche's Hemlibra Wins Expanded FDA Approval, Opening The Door To Broad Hemophilia A Opportunity

Hemlibra was approved to prevent or reduce bleeding in adults and children with hemophilia A without factor VIII inhibitors, a significantly larger patient population than its current indication in patients with factor VIII inhibitors.